Treatment of Charcot foot osteoarthropathy has emerged as a major component
of the American Orthopaedic Foot and Ankle Society (AOFAS) Diabetes 2000 I
nitiative. A two-part survey described treatment patterns and current footw
ear use of patients with Charcot osteoarthropathy of the foot and ankle. In
the first part, 94 consecutive patients with a history of Charcot foot and
ankle presenting for care were questioned on their foot-specific treatment
and current footwear use. A history of diabetic foot ulcer was given by 39
(41%) patients, and an infection had been present in a foot of 20 (21%) pa
tients. The initial treatment of the Charcot foot and ankle had been a tota
l contact cast in 46 (49%) patients, and a pre-fabricated walking boot in 1
9 (20%). Charcot related surgery had consisted of 76 procedures in 46 (49%)
patients. Sixty-three (67%) patients were currently using accommodative fo
otwear (depth-inlay shoes in 46 [49%], custom shoes in 10 [11%], and CROW i
n 7 [7%] patients), and 72 (77%) were currently using custom accommodative
foot orthoses.
The second part of this study consisted of a questionnaire completed by 37
orthopaedic surgeons (members of AOFAS) interested in forming a Charcot Stu
dy Group. They treated an average of 11.8 patients having Charcot foot or a
nkle per month. Thirty (81%) used the Semmes-Weinstein 5.07 monofilament as
a screening tool for peripheral neuropathy. For treatment of Eichenholtz S
tage 1, 29 (78%) used a total contact cast and 15 (41%) allowed weightbeari
ng; for Stage 11, 30 (81%) physicians used a total contact cast and 18 (49%
) allowed weight-bearing.
Although the literature contains uniform recommendations for immobilization
and non-weightbearing as treatment for the initial phases of Charcot arthr
opathy, the results of this benchmarking study reveal that current treatmen
t is varied.